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Abstract
Objective. To evaluate the influence of combined therapy of Sitagliptin and metformin 
on fat metabolism in patients with Т2 DM.
Methods. The study included 82 patients with obesity. The following were evaluated at 
base line and after 6 months of therapy: fasting glucose, postprandial glucose, glycated 
hemoglobin, weight, waist circumference, lipid profile, proinsulin, leptin,adiponectin, 
HOMA-β,HOMA-IR, MRI of visceral fat.
Results. After 6 months, HbA1c decreased by 18.52% (p < 0.001) in-group 1 and by 8.17% 
(p < 0.001) in-group 2. HOMA-β increased by 33% in group 1 (p < 0.001) and by 11% in 
group 2 (p > 0.05). Adiponectin levels increased by 27.06% (p < 0.001) in group 1 and by 
7.16% in group 2 26 (p < 0.001). Leptin levels were reduced by 30.47% (p < 0.001) in group 1 
and by 5.41% in group 2 (p < 0.001). MRI showed a 7.52% reduction in visceral fat for group 
1 (p < 0.001) and a 1.76% reduction for group 2 (p < 0.01).
Conclusion. Sitagliptin and metformin combination therapy had a prominent effect on 
nonglycemic parameters, with more marked decreases in visceral fat and leptin and 
increases in adiponectin levels.
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1. Introduction
Diabetes mellitus (DM) occupies a prominent place among chronic diseases due to the 
rapid spread, tendency to increase in the number of patients, high disability due to numer-
ous macro- and microvascular complications and the leading position among the main 
causes of death [1]. The relationship between epidemics of type 2 diabetes and obesity 
initiated conducting research studying the adipose tissue as an endocrine organ that plays 
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a crucial role in the development of metabolic disorders in patients suffering from obesity. 
Due to excessive accretion of visceral adipose tissue, there is an imbalance of adipokines, 
lipid metabolism, hyperinsulinemia, which lead to the development and progression of 
insulin resistance (IR), DM 2. According to modern concepts, in the pathogenesis of DM 
2, in addition to IR and impaired insulin secretion, an important role is played by abnor-
malities related to the “incretin effect,” which led to the creation of a class of inhibitors 
of dipeptidyl peptidase-4 (iDPP-4). The advantage of this class is the restoration of the 
physiological concentration of glucagon-like peptide-1 (GLP-1). Due to the physiological 
mechanism of action, the use of drugs of this class is associated with a low risk of hypo-
glycemia. It should be noted that therapy with DPP-4 inhibitors, along with glycemic ones, 
also has favorable nonglycemic effects, among which, a positive effect on body weight 
(BW), lipid profile and blood pressure (BP) [2–5]. One of the first approved representatives 
of iDPP-4 (registered by the FDA in 2007) is Sitagliptin. According to the literature, the 
use of Sitagliptin has been studied both in the form of monotherapy, and in double, triple 
combinations of hypoglycemic drugs combined with insulin [6–12]. Particular attention 
is drawn to the possibility of the combination of iDPP-4 with a first line drug-metformin. 
It is important to note that metformin can lead to an increase in total GLP-1 and poten-
tially enhance the effects of the inhibitor DPP-4 [13]. The combination of metformin and 
iDPP-4 suggests an impact on all the major pathogenetic mechanisms of development of 
type 2 diabetes type [14]. A number of studies [15, 16] reported the identification of DPP-4 
as a new adipokine, which can be a link between an increase in adipose tissue mass and 
obesity-associated diseases. The excessive content of DPP-4 in visceral adipose tissue may 
be a marker of inflammation of adipose tissue, which is associated with insulin resistance. 
Conversely, animal studies have shown that suppression of DPP-4 prevents the develop-
ment of inflammation and impaired glucose tolerance, which develops on the background 
of obesity, in adipose tissue.
Thus, due to poor knowledge, a comprehensive study of lipid metabolism, with the visual-
ization of fat dynamics, the evaluation of adipocytokine-adiponectin and leptin secretion, 
and the possibility of disease management by changing the parameters of lipid metabolism, 
on the background of iDPP-4 therapy in combination with metformin, the best variant of 
physiological intervention mobilizing the body’s own resources, is of the scientific and prac-
tical interest, which determined the relevance of the study. The solution of this problem will 
allow us to expand our understanding of the nonglycemic effects of iDPP-4, to improve the 
effectiveness of therapy in patients with type 2 diabetes and obesity. The study was con-
ducted at the Department of Endocrinology of the Russian Medical Academy of Postgraduate 
Education.
The aim of our study was to evaluate the effect of combined therapy with Sitagliptin and 
metformin on the parameters of fat metabolism in patients with type 2 diabetes and obesity.
The study protocol was approved by the expert commission of therapeutic faculty of the 
State-Funded Educational Institution “Russian Medical Academy of Postgraduate Education” 
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of the Ministry of Health of Russia on issues of medical ethics 14.11.2013 (Minutes № 8 of 
14.11.2013).
Materials and methods. The study included 82 patients with type 2 diabetes with exces-
sive body weight of varying severity, dyslipidemia, not taking lipid-lowering therapy, who 
did not reach the target levels of HbA1c on metformin monotherapy and dietary treatment. 
The average age of the patients was 55.3 ± 9.1 years. Group I included 42 patients with type 
2 diabetes and obesity on combination therapy with metformin 2000 mg/day + Sitagliptin 
100 mg/day. Before entering the study, patients in this group received monotherapy with 
metformin at a dose of 1500–2000 mg/day. Group II included 40 patients on metformin alone 
at a dose of 2000 mg/day. Before entering the study, patients were on dietary treatment. All 
patients were overweight and obese. A brief description of the groups by main parameters 
is presented in Table 1.
After the formation of comparable clinical groups, all patients underwent clinical, instru-
mental and laboratory tests. Methods of examination included the collection of anamnesis, 
measurement of anthropometric parameters (height, body weight (BW), waist circumference 
(WC), hip circumference (HC) and their ratio).
To evaluate the carbohydrate metabolism, the levels of fasting plasma glycemia (GH), post-
prandial glycemia (PPG) and glycated hemoglobin (HbA1c) were determined.
For the study of fat and lipid metabolism, the concentrations of leptin, adiponectin, total 
cholesterol (OX), triglycerides (TG), high-density lipoprotein (HDL) cholesterol, low-density 
lipoprotein (LDL) cholesterol and apolipoprotein β (apo β protein) were determined.
The quantity and nature of the distribution of adipose tissue were assessed by MRI of visceral 
fat at L4 level. The area of visceral fat (VFA) ≥ 130 cm2 and the ratio of VFA/SFA > 0.4 were 
interpreted as visceral obesity.
Insulin resistance and functional activity of β-cells were determined using the HOMA IR and 
HOMA β indices. The calculation was carried out according to the following formulas:
HOMA IR = Fasting insulin (μE/ml) X Fasting plasma glucose (mmol/L)/22.5.
Index of HOMA-IR <2.77 was considered normal. IRI-immunoreactive insulin.
HOMA β = 20X IRI (μU/ml)/fasting glycemia (mmol/L) −3.5.
A biochemical blood test was performed on Advia 1800 automatic analyzers from Bayer (Germany) 
and Olympus AU 2700 from Beckman Coulter (USA). The level of HbA1c was determined by 
capillary electrophoresis on a Capillaris 2 device from Sebia (France). The study of the content 
of adiponectin was carried out by ELISA (immunoenzyme method) with Bio Vendor test sys-
tems (Germany). The levels of leptin and proinsulin were evaluated using DRG kits for enzyme 
immunoassay on the Multiscan Labsystems analyzer (Finland). Insulin level in serum of venous 
blood was evaluated by the method of chemiluminescent immunoassay on the automatic device 
Architect i2000 (Abbot, USA). The level of C-peptide was determined in the serum of venous 
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blood by the method of chemiluminescent immunoassay on the Immulite 2000 automatic analyzer 
(Siemens, USA). To assess the lipid profile, the levels of OX, HDL cholesterol, LDL cholesterol and 
TG in serum were determined after 12 h of fasting by enzymatic colorimetry on automatic Advia 
1800 analyzers. Apolipoprotein β (apo-β-protein) was determined by immunoturbidimetry using 
an Olympus AU 400 automatic analyzer, manufactured by Beckman Coulter (USA).
Before entering the study, patients provided written informed consent, were trained in the 
school of diabetes, were secured by means of self-control and self-monitoring diaries.
The statistical analysis of the data was carried out using the Statistica 8 software package. The 
Wilcoxon test was used to assess the difference in the parameters before and after treatment. 
The difference in dynamics between the groups was determined by the Mann–Whitney U 
test. The pair relationships of the indicators were determined by the Spearman rank correla-
tion coefficient.
Group characteristics by main parameters
Parameters Group 1 Group 2 P
Total number of patients, abs% 42 (100) 40 (100) —
Men’s, abs. (%) 10 (23.8) 8 (20) —
Women, abs. (%) 32 (76.1) 32 (80) —
Average age, years 55.3 ± 9.1 56.1 ± 5.4 >0.05
Duration of DM type 2, years 2.4 ± 2.0 2.4 ± 1.5 >0.05
Fasting glycemia, mmol/l 9.7 ± 279 9.6 ± 2.1 >0.05
Postprandial glycemia, mmol/l 11.01 ± 3.19 9.45 ± 1.96 <0.05
HbA1c, % 8.3 ± 1.66 8.35 ± 1.7 >0.05
Total cholesterol, mmol/l 6.85 ± 0.95 7.11 ± 6.39 >0.05
Adiponectin, μkg/ml 7.63 ± 2.56 7.41 ± 2.43 >0.05
Leptin, ng/ml 23.87 ± 13.43 23.84 ± 9.61 >0.05
BMI, kg/m2 34.78 ± 4.87 35.45 ± 4.3 >0.05
Visceral fat area (VFA, L4), sm2 300.73 ± 80.88 334.62 ± 70.55 >0.05
Subcutaneous fat area (SFA, L4), sm2 375.88 ± 91.55 431.25 ± 54.13 >0.05
Proinsulin, pmol/l 9.66 ± 10.49 10.02 ± 12.65 >0.05
Insulin, μU/ml 14.24 ± 9.3 14.72 ± 8.51 >0.05
C-peptide, ng/ml 3.3 ± 1.6 3.2 ± 1.7 >0.05
HOMA-β 40.63 ± 25.99 57.05 ± 35.43 >0.05
HOMA-IR 5.85 ± 4.15 6.32 ± 5.0 >0.05
Table 1. Characteristics of groups by main parameters.
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To test the statistical hypotheses on the type of distribution, the Shapiro-Wilks criterion was 
applied. The significance level of p was set at 0.05.
The design of the study is shown in Figure 1.
2. Anthropometric measures
After 24 weeks of therapy, a significant decrease in all anthropometric measures was observed in 
both groups, but more statistically significant differences were observed in group I. BMI decreased 
on average by 1.81 ± 1.33 (5.29%), p < 0.001 in group I, and by 0.68 ± 0.35 (1.96%), p < 0.001 in 
group II. Body weight (BW) decreased by 4.97 ± 3.22 kg (5.2%), p < 0.001 in group I, and by 
2 ± 0.94 kg (2.07%), p < 0.001 in group II. Waist circumference (WC) decreased by 6.52 ± 4.71 cm 
(5.88%), p < 0.001 in group I and by 2.42 ± 1.06 (2.18%), p < 0.001 in group II. Accordingly, WC/HC 
ratio decreased from 0.95 ± 0.06 to 0.91 ± 0.05 (3.28%), p < 0.001 in group I, and from 0.94 ± 0.03 
to 0.93 ± 0.03 (0.98%), p < 0.001 in group II (Figure 2). The decrease in WC as well as in the WC/
HC ratio indicates a decrease in the amount of visceral fat, which means a decrease in insulin 
resistance and hyperinsulinemia, the underlying basis of the metabolic syndrome.
The decrease of body weight on Sitagliptin and metformin combined therapy is likely associ-
ated with an integrated effect from caloric restriction of the diet, a synergistic effect of iDPP-4 
and metformin on GLP-1, which has an anorectic effect.
Total of 82
paent, with
DM type 2
and obesity
1 gr, n=42
sitaglipn+мeormin
0,1/2,0 g/d
2 gr,n=40
меormin 2,0 g/d
clinical and instrumental examinaon
Carbohydrate
metabolism (GF,
PPG, HbA1c)
Hormones of
adipose ssue
(lepn,
adiponecn)
Funconal acvity of
pancreac β-cells
(proinsulin, insulin, C-
pepde, HOMA β + HOMA
IR)
МRI visceral fat (VFA, SFA,
VFA/CFA)
Figure 1. Study design.
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3. Carbohydrate metabolism
After 24 weeks, a significant decrease in all parameters of carbohydrate metabolism was 
observed in group I. Level of FPG in group I decreased by 2.67 ± 2.37 mmol/L (21%), р <0.001, 
FPG decrease in group II has not reached statistical significance with the mean decrease of 
0.33 ± 1.6 mmol/L (1.45%), р > 0.05. Postprandial glucose (PPG) decreased by 3.26 ± 2.54 mmol/L 
(26.35%), р <0.001 in group I and by 0.64 ± 1.2 mmol/L (5.31%), p < 0.05 in group II. HbA1c level 
decreased by 1.63 ± 1.31% (18.52%), р <0.001 in group I, and by 0.72 ± 0.47% (8.17%) in group II 
(Figure 3).
The largest success in achieving glycemic control in patients on combined treatment is associ-
ated with complimentary action of the therapy components. Metformin lowers insulin resis-
tance and hepatic glucose production, while Sitagliptin delays inactivation of GLP-1, thus 
enhancing glucose-dependent insulin secretion and decreasing glucagon secretion [17]. In 
addition, it was demonstrated that metformin leads to increase in overall GLP-1 and can 
Figure 3. Dynamics of carbohydrate metabolism in the groups. GF-glucose fasting, PPG-postprandial glycemia; 
*P < 0.05; ** P > 0.05.
Figure 2. Dynamics of anthropometric parameters. P < 0.001 for all values; P between groups <0.001 for all value.
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potentially enhance the effects of DPP-4 inhibitor. It is notable that the study achieved a 
significant PPG decrease in metformin monotherapy group, which is potentially associated 
with metformin ability to increase GLP-1 level and to slow down carbohydrate absorption in 
the intestine.
4. Lipid profile
Lipid profile parameters belong to the improvement indices of the metabolic health.
The analysis of the lipid profile showed significant positive dynamics of TC, HDL and Apo 
B in both groups. The only difference between groups was in HDL and TG dynamics. HDL 
level decreased by 0.78 ± 0.5 mmol/L (17.43%), p < 0.001 in group I, and by 0.37 ± 0.17 mmol/L 
(9.63%), р <0.001 in group II; TG decreased by 1.33 ± 1.16 mmol/L (28.15%), p < 0.001 in group 
I, and by 0.63 ± 0.39 mmol/L (15.19%), р <0.001 in group II. Figure 4 displays parameter 
dynamics in both groups.
Possible mechanisms partaking in the positive effect on lipid profile from therapy by DPP-4 
inhibitor in combination with metformin could be weight loss, lowering of glucose level, 
decrease in visceral fat (VF), which is accompanied by improvement in metabolic status.
5. Subcutaneous and visceral fat
MRI visualization of visceral fat dynamics demonstrated positive fat redistribution by low-
ering VFA in group I by 20.62 ± 13.54 cm2 (7.52%), р <0.001. In group II of metformin mono-
therapy, VFA decreased by 5.77 ± 3.75 cm2 (1.76%), р <0.001. SFA decreased by 4.51 ± 14.43 cm2 
(1.69%), p < 0.05 in group I, and by 1.95 ± 1.05 cm2 (0.46%), p < 0.05 in group II. Significant 
improvement in SFA dynamic was observed in both groups; however, we have not detected 
Figure 4. Dynamics of lipid profile. *** P < 0.001; **P < 0.05; *P > 0. 05 between groups.
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statistically significant difference between the groups (Figure 5). VFA/SFA ratio significantly 
lowered by 0.18 ± 0.24 (15.26%), p < 0.001 in group I; and by 0.008 ± 0.008 (1.14%), p < 0.001 in 
group II, which is also indicative of more marked lowering of visceral fat in group I.
6. Adipose tissue hormones
Of note, decrease in VFA and improvement in anthropometric measures were associated to 
change in secretion of adipose tissue hormones. On Sitagliptin and metformin therapy, a more 
marked decrease in leptin level by 7.37 ± 5.69 ng/ml (30.47%), р <0.001 was registered, while 
on metformin monotherapy, leptin level decreased by 1.21 ± 1.34 ng/ml (5.41%), р <0.001.
The study also indicates dynamics of another adipokine-adiponectin that plays a significant 
role in glucose and lipid metabolism. The initial adiponectin levels in both groups were lower 
than reference values. After 6 months of therapy, a more marked adiponectin level increase by 
1.95 ± 1.53 μg/mL (27.06%), р <0.001 was observed in group I compared to group II, where it 
is increased by 0.49 ± 0.26 μg/mL, (7.16%), р <0.001. It is known that this hormone secretion is 
diminished at T2D. The recovery of secretion is accompanied by the improvement in carbohy-
drate metabolism indicators, lowering of atherogenesis and slowing down of the progression 
of diabetes vascular events [18].
Adipose tissue hormones dynamics is displayed in Figure 6.
Thus, visceral fat area increased on the background of increasing concentration of adiponec-
tin and decreasing leptin content.
Figure 5. Dynamics of visceral and subcutaneous fat by results MRI. VF-visceral fat, SF- subcutaneous fat; *P between 
groups >0.05; **P between groups <0.05.
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7. Functional activity of β-cells and HOMA-IR
Data from the analysis of pancreatic β-cell function condition have certain scientific and 
practical interest. For instance, in the Sitagliptin and metformin combined therapy group, 
a significant increase in HOMA-β index by 23.4 ± 22.6 relative units (33.06%), р <0.0001 was 
observed compared to the group that receiving metformin monotherapy, where increase 
in this index has not reached a statistical significance and equaled 4.86 ± 1.63 relative units 
(11.08%), р > 0.05.
Furthermore, the work has obtained statistically significant insulin level lowering in both 
groups. For instance, on a background of Sitagliptin therapy in combination with metformin 
therapy, insulin level decreased by 15.68%, (р <0.001), and on metformin monotherapy, insu-
lin level decreased by 7.57%, (р <0.001).
Before treatment, both groups showed increase in proinsulin level, after 6 months of therapy, 
we achieved significant decrease in the proinsulin level in group I (Sitagliptin + metformin) 
by 29.17%, (р <0.001), and in group II (metformin) by 13.79%, (p < 0.001). Proinsulin/insulin 
ratio is increased when the functional activity of β-cells is decreased and is an indication 
of more marked apoptosis in pancreatic β-cells. We established that on Sitagliptin therapy 
in combination with metformin, a significant decrease by 10.38%, (р <0.05) was observed in 
proinsulin/insulin ratio, while in metformin monotherapy group, a decrease in this ratio was 
insignificant, by 2.84%, (p > 0.05) (Figure 7). This should be considered as a long-term positive 
effect of Sitagliptin on the function of pancreatic β-cells.
It is important to note that on combined therapy С-peptide level increased by 55.83%, 
(р < 0.0001); and by 6.3%, (р < 0.05) in metformin monotherapy group. HOMA-IR significantly 
lowered in both groups. However, we have not detected statistically significant difference 
between the groups’ dynamics. It decreased by 32% (р < 0.0001) in group I, and by 11.05% 
(р < 0.0001) in group II. The decrease in homeostasis model assessment of insulin resistance is 
the evidence of improvement in peripheral glucose disposal. Positive effect on β-cell function 
is associated with lowering of glucotoxicity, weight loss, insulin resistance, and improvement 
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Figure 6. Dynamics of adipokines.
DPP-4 Inhibitors and Fat Metabolism in Patients with Type 2 Diabetes
http://dx.doi.org/10.5772/intechopen.72078
63
in metabolic health, which promoted lowering of the “stress” on the insular apparatus of the 
pancreas. β-cell function improvement is promising in stabilization of T2D progression.
The results of the correlation analysis are displayed in Table 2 and in Figure 8.
Thus, as can be seen from the correlation analysis, an additional therapeutic effect on glyce-
mic control in patients with T2D and obesity is associated with a decrease in the amount of 
visceral fat and a change in the secretion of adipose tissue hormones. Table 3 presents a com-
parative analysis of the main parameters, depending on the type of therapy.
Показатели, динамика Адипонектин Лептин
HbA1c r = −0.39* r = 0.32*
VF r = −0.54* r = 0.33*
body mass r = −0.75** r = 0.45**
BMI r = −0.74** r = 0.45**
WC r = −0.62** r = 0.43**
LDL r = −0.29** r = 0.3**
TG r = −0.33** r = 0.16
HOMA IR r = −0.53** r = 0.37**
HOMA β r = 0.29** r = −0.33**
Leptin r = −0.63* —
*p < 0.01 significance of correlation coefficient at р < 0.01.
**р < 0.05 significance of correlation coefficient at p < 0.05.
Table 2. Correlation analysis.
Figure 7. Function of β-cells of the pancreas and HOMA IR in dynamics. *P between groups <0.05.
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8. Discussion
The study investigates the effect of Sitagliptin in combination with metformin as well as 
of metformin monotherapy on carbohydrate and fat metabolism in patients who required 
their therapy to be intensified. According to the data received, after 24 weeks, the posi-
tive dynamics of HbA1c was followed by a significant decrease in mean fasting glycemia 
and postprandial glycemia in group I, while in group II (on metformin monotherapy), the 
Figure 8. Correlation between the dynamics of the VF and HbA1c.
Parameters Group 1,
Sitagliptin + metformin
Group 2,
Metformin
P 
between 
groups
Before treatment After treatment Before treatment After treatment
HbA1c 8.3 ± 1.66 6.66 ± 1.24 8.35 ± 1.75 7.62 ± 1.39 <0.001
BMI, kg/m2 34.78 ± 4.87 32.96 ± 5.04 35.45 ± 4.3 34.76 ± 4.33 <0.001
Adiponectin, 
mkg/ml
7.63 ± 2.56 9.59 ± 3.03 7.41 ± 2.43 7.9 ± 2.44 <0.001
Leptin, ng/ml 23.87 ± 13.43 16.49 ± 9.63 23.87 ± 9.61 22.66 ± 9.61 <0.001
VF, sm2 300.73 ± 80.88 280.11 ± 84.16 334.62 ± 70.55 328.85 ± 70.4 <0.001
SF, sm2 375.88 ± 91.55 371.37 ± 98.04 431.25 ± 54.13 429.3 ± 54.52 >0.05
LDL, mmol/l 4.31 ± 0.73 3.53 ± 0.58 3.89 ± 0.61 3.51 ± 0.61 <0.001
ТG, mmol/l 4.28 ± 2.4 2.95 ± 1.73 4.31 ± 2.04 3.68 ± 1.86 <0.05
HOMA-IR 5.85 ± 4.15 3.49 ± 2.44 6.32 ± 5.0 4.32 ± 2.77 >0.05
HOMA-β 40.63 ± 25.99 64.04 ± 29.01 57.05 ± 35.43 61.91 ± 30.82 <0.005
Table 3. Comparative characteristics of the main parameters depending on the type of therapy.
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decrease in glycemia did not reach statistical significance. An important advantage in our 
study was that, despite the common belief about neutral effect that DPP-4 inhibitors have 
on weight, we demonstrated that with the addition of Sitagliptin to metformin, there was a 
more marked weight loss and decrease of BMI and visceral fat depot, compared to the group 
of patients on metformin monotherapy. What was a “pure” contribution of DPP-4 inhibitor 
+ metformin combination, and what was due to lifestyle changes in both groups could not 
be determined in this work, therefore, further prospective studies including quantitative 
calculation of energy inputs are required. The study of adipokine status, specifically leptin 
and adiponectin, was of particular interest. The main function of leptin is forming a com-
munication pathway link between adipocytes and the brain [19]. Leptin secretion positively 
correlates with the amount of adipose tissue, which we also demonstrated in our work. 
In addition to the anorectic effect in the adjustment of eating behavior, leptin also stimu-
lates energy intake. During increased energy intake exceeding the body’s requirements, 
the leptin level increases, which prevents further food consumption and increases energy 
expenditure, and that leads to negative energy balance and rebalancing of energy. Most 
obese patients have high leptin levels, but this does not lead to weight loss, which confirms 
the fact that obese patients may develop resistance to leptin. Leptin’s effect disorder in 
obesity can be a leading factor in the development of insulin resistance and fat and glucose 
metabolism disorder. In our work, on a background of combined Sitagliptin and metfor-
min therapy, the leptin level was reduced by 30.47% and in the metformin monotherapy 
group by 5.41%. We associate decrease in leptin level with weight loss and a decrease in the 
amount of fat.
In both study groups, the initial adiponectin levels were lower than reference values. After 
24 weeks of therapy, adiponectin content in blood increased by 27.06% in the group receiv-
ing Sitagliptin and metformin combination, and by 7.16% in the group receiving metformin 
monotherapy. Adiponectin with its effect on the reduction of insulin resistance, which is char-
acteristic of patients with T2D and obesity, and also its anti-inflammatory, antidiabetic and 
antisclerotic effects make it an additional therapeutic target. In our study, an increase of adi-
ponectin is most likely associated with a decrease of body weight and VFA, according to the 
data of the correlation analysis. However, there are publications which make it known that 
GLP-1 promotes an increase in adiponectin level [20, 21], the Sitagliptin therapy was followed 
by increase in adiponectin level [22, 23].
Correlational analysis demonstrated correlation of glycemic control in T2D obese patients 
with reducing visceral fat amount and with recovery of secretion of adipose tissue hormones.
In addition, the study showed a significant improvement in the functional activity of pan-
creatic β-cells against combined Sitagliptin and metformin therapy, which was confirmed 
by an increase in the HOMA-β index, a decrease in the ratio of proinsulin/insulin, in con-
trast to metformin monotherapy, where the change in these indices did not reach statis-
tical significance. A possible mechanism for improving the function of β-cells can be a 
decrease in lipotoxicity, against a background of a decrease in the level of TG inhibiting 
β-cell function.
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9. Conclusion
Our study demonstrated the important role of correction of fat metabolism disorders in 
improving glycemic control in patients with diabetes and obesity. Regression of visceral fat 
according to the MRI results was accompanied by the recovery of levels of adipokine hor-
mones, which led to an improvement in the parameters of carbohydrate and fat metabolism. 
Contrary to common belief, we consider Sitagliptin as a drug that promotes weight loss. The 
chapter demonstrates that ultimately it is the reduction of the visceral depot that plays a 
key role in the correction of carbohydrate metabolism disorders. The parameters of the lipid 
profile and glycemic control are significantly improved as the pathogenetic effect on patient’s 
body weight as well as on the structure of its adipose tissue. Recovery of such indicators as 
HOMA-IR and HOMA-β proves the possibility of disease management by correcting disor-
ders of fat metabolism in patients with T2D and obesity in the early stages.
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